The anxiolytic effects and excretion of cannabinoids in humans

This study is divided into three parts. The first part aimed to investigate the cannabidiol anxiolytic effect in treatment-nave individuals with social anxiety disorder through simulation of public speaking. The second part evaluated healthy subjects' anxiety during a public speaking test following a high rimonabant oral dose, to understand better the possible pharmacological approaches for anxiety disorder treatment. Finally, the third part aimed to monitor cannabinoid blood concentrations during sustained abstinence from chronic daily cannabis smoking. These findings can extend our knowledge on medical use of cannabinoids and impact development of per se laws to reduce morbidity and mortality from cannabis-impaired driving.